We are bringing a new generation of vaccines to empower people everywhere to live healthy lives.
We are bringing a new generation of vaccines to empower people everywhere to live healthy lives.
A Better Vaccine: IVT PCV-25
Our lead candidate, Pneumococcal Conjugate Vaccine for Paediatric, leverages the Inventprise proprietary Linker Conjugation Platform to result in a longer-lasting vaccine with more coverage and a better immune response.
Proprietary Linker Conjugation Platform
Inventprise’s proprietary scalable conjugation technology based on the Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker designed to create specific, highly immunogenic, and broad-spectrum conjugate vaccines.
Proprietary Linker Conjugation Platform
Inventprise’s proprietary scalable conjugation technology based on the Hydrazied-PEG-Hydrazide (Hz-PEG-Hz) linker designed to create specific, highly immunogenic, and broad-spectrum conjugate vaccines.
READ MORE
State-of-the-Art, Highly Automated Manufacturing with Capacity to Supply Global Demand.
State-of-the-Art, Highly Automated Manufacturing with Capacity to Supply Global Demand
Recent Inventprise News
PRESS RELEASE New Inventprise Pneumococcal Vaccine Enters Phase 1/2 Clinical Evaluation The pneumococcal conjugate vaccine is designed to broaden protection against life-threatening childhood pneumonia and
Highly automated manufacturing facility is expected to provide lifesaving vaccines to low- and middle-income countries, with additional supply to meet global demand.
PRESS RELEASE Inventprise Receives $30M, Appoints New CEO and Expands Corporate Board Funding is the first tranche of up to $90M from Bill & Melinda